Activity of D-carnitine and its derivatives on Trypanosoma infections in rats and mice

M Manganaro1, M T Mascellino, L Gradoni

  • 1Department of Infectious Diseases, University of Rome La Sapienza, Rome, Italy.

Parasite (Paris, France)
|July 10, 2003
PubMed

Insights

D-carnitine shows promise for treating African trypanosomiasis. It competitively inhibits parasite growth by interfering with energy production, offering a potential new therapeutic strategy with low toxicity.

Area of Science:

  • Parasitology
  • Biochemistry
  • Pharmacology

Background:

  • African trypanosomiasis treatment has seen limited advancement.
  • L-carnitine is crucial for trypanosome energy metabolism (ATP production).

Purpose of the Study:

  • To investigate D-carnitine's potential to inhibit Trypanosoma parasite replication.
  • To explore D-carnitine as a competitive inhibitor of L-carnitine's metabolic pathway.

Main Methods:

  • Testing D-carnitine formulations in rodent models infected with Trypanosoma lewisi and T. brucei rhodesiense.
  • Assessing toxicity and parasite growth inhibition.

Main Results:

  • High oral doses of D-carnitine were non-toxic to rodents.
  • D-carnitine induced approximately 50% reversible parasite growth inhibition.
  • A potential mechanism involves interference with pyruvate kinase activity and ATP production.

Conclusions:

  • D-carnitine demonstrates non-toxic, competitive inhibition of African trypanosome growth.
  • D-carnitine may serve as an adjunct therapy for African trypanosomiasis alongside existing drugs.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...